{
  "docId": "019de073-4472-76ed-a8f3-3d6ae669b88a",
  "docSlug": "6078678dfcf31020360c86ce90f559c0",
  "documentTitle": "BioNTech | Results Presentation Deck | 32 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 32,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-4472-76ed-a8f3-3d6ae669b88a/8",
  "deckHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a",
  "deckJsonHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a.json",
  "deckAnchorHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.268,
        "y": 0.545
      },
      "kind": "list",
      "text": "BNT122 (iNeST): Positive data from Phase 1 trial; BNT116 (FixVac): FPD in Phase 1 trial; BNT142 (RiboMab): FPD in Phase 1/2 trial; BNT211 (CLDN6 CAR-T): EMA PRIME designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20ec36bf-3305-49eb-917f-8dd6a3881a71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.268,
        "y": 0.298
      },
      "kind": "list",
      "text": "Reported Q2 total revenues of €3.2 bn and year-to-date revenues of €9.6 bn; Began construction of first BioNTainer mRNA vaccine manufacturing facility in Africa; Signed new equal share cost/profit collaboration agreement with Genmab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca478450-e93b-49cc-8f3c-e1412f4707e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.81,
        "x": 0.048,
        "y": 0.905
      },
      "kind": "source-note",
      "text": "1 BioNTech's profit share is estimated based on preliminary data... 2 Investigator-initiated trial",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "206465e1-cc4c-439b-b627-baf165e65bf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.144,
        "w": 0.418,
        "x": 0.048,
        "y": 0.058
      },
      "kind": "title",
      "text": "Highlights in Q2: Corporate & Oncology Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b673eea-8906-459f-94c1-1bd20281250d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}